8-K: Lexicon Pharmaceuticals Reports Positive Phase 2b Results and Full Year 2024 Financials

Lexicon Pharmaceuticals announces positive topline results from its Phase 2b PROGRESS study of pilavapadin for diabetic peripheral neuropathic pain and reports increased revenue for 2024.

Summary

• Lexicon Pharmaceuticals reported its fourth quarter and full year 2024 financial results and provided business updates.
• The company's strategy focuses on advancing its R&D pipeline.
• Topline results from the Phase 2b PROGRESS study of pilavapadin showed the 10 mg dose achieved meaningful pain reduction versus placebo and was well-tolerated.
• Lexicon is on track for an IND filing for LX9851 in obesity in 2025.
• Enrollment continues for the Phase 3 clinical trial of sotagliflozin in hypertrophic cardiomyopathy (HCM).
• Revenues for the fourth quarter of 2024 increased to $26.6 million from $0.7 million in 2023.
• Full year 2024 revenues increased to $31.1 million from $1.2 million in 2023, driven by increased sales of INPEFA and an upfront payment from Viatris.
• Research and development expenses for the fourth quarter of 2024 increased to $26.7 million from $14.8 million in 2023.
• Full year research and development expenses for 2024 increased to $84.5 million from $58.9 million in 2023.
• Selling, general, and administrative expenses for the fourth quarter of 2024 decreased to $32.3 million from $32.6 million in 2023.
• Full year 2024 selling, general, and administrative expenses increased to $143.1 million from $114.0 million in 2023.
• Net loss for the fourth quarter of 2024 was $33.8 million, or $0.09 per share, compared to a net loss of $49.8 million, or $0.20 per share, in 2023.
• Net loss for the full year 2024 was $200.4 million, or $0.63 per share, compared to a net loss of $177.1 million, or $0.80 per share, in 2023.
• As of December 31, 2024, Lexicon had $238.0 million in cash and short-term investments, compared to $170.0 million as of December 31, 2023.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with positive clinical trial results and revenue growth, but also significant net losses and increased R&D expenses. The focus on pipeline advancement and potential market opportunities contributes to a moderately positive outlook.

Positives

• Positive topline results from the Phase 2b PROGRESS study of pilavapadin support advancement to Phase 3 development.
• LX9851 for obesity is progressing towards an IND submission in 2025.
• Sotagliflozin continues to generate differentiating clinical data, including a publication in The Lancet Diabetes & Endocrinology.
• Revenues increased significantly in both the fourth quarter and full year 2024.
• Lexicon's cash position improved to $238.0 million.

Negatives

• The 20 mg dose arm of the PROGRESS study did not reach statistical significance on its primary endpoint.
• The company discontinued preparation for a potential Zynquista launch in type 1 diabetes following a complete response letter from the FDA.
• Lexicon reported a net loss of $33.8 million for the fourth quarter and $200.4 million for the full year 2024.
• Selling, general and administrative expenses increased to $143.1 million from $114.0 million for the full year 2023.

Risks

• The company's ability to meet its capital requirements is a risk.
• Successfully commercializing approved products and obtaining regulatory approvals for other drug candidates on anticipated timelines are uncertain.
• Manufacturing, intellectual property rights, and the therapeutic or commercial value of approved products and other drug candidates pose risks.
• The company's reliance on strategic alliances could impact future performance.

Future Outlook

Lexicon plans to initiate Phase 3 trials for pilavapadin in DPNP in 2025 and is on track for an IND filing for LX9851 in obesity in 2025. Enrollment continues for the Phase 3 clinical trial of sotagliflozin in hypertrophic cardiomyopathy (HCM).

Management Comments

• With R&D efforts our core priority, we were pleased to report progress on three programs, said Mike Exton, Ph.D., Lexicons chief executive officer and director.

Industry Context

Lexicon is focusing on areas of significant unmet need, such as neuropathic pain, obesity, and hypertrophic cardiomyopathy, where there is potential for new or differentiated therapies. The company is competing with other pharmaceutical companies developing treatments for these conditions.

Comparison to Industry Standards

• The ischemic benefit of sotagliflozin on both heart attack (myocardial infarction, or MI), and stroke reduction has not been observed with other SGLT inhibitors.
• Lexicon is targeting the neuropathic pain market with pilavapadin, aiming to be the first oral non-opioid drug therapy approved in more than 20 years, which would differentiate it from existing treatments like gabapentin and pregabalin.

Stakeholder Impact

• Shareholders may react positively to the clinical trial progress and revenue growth.
• Employees are impacted by the company's strategic repositioning and reduction in field force.
• Patients with DPNP, obesity, and HCM may benefit from the development of new therapies.
• The Viatris licensing agreement impacts the commercialization of INPEFA.

Next Steps

• Initiate Phase 3 trials for pilavapadin in DPNP in 2025.
• Submit an IND application for LX9851 in obesity in 2025.
• Continue enrollment in the SONATA HCM Phase 3 clinical trial.
• Select a future medical meeting for release of additional clinical data for pilavapadin later this year.
• End of Phase 2 meeting with FDA for Pilavapadin.

Key Dates